Financial Results and related party transaction for year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Smruthi Organics Ltd posted full-year revenue from operations of ₹12,600.79 lakhs, with total income of ₹12,609.67 lakhs. Net profit for the year stood at ₹356.28 lakhs, translating to an EPS of ₹3.11. In the fourth quarter alone, revenue was ₹3,809.45 lakhs and net profit was ₹223 lakhs (EPS ₹1.95). The Board has recommended a dividend of ₹1.5 per share (15%) on the equity capital of ₹11.45 crore. The API segment drove almost all of the revenue (₹12,565 lakhs) and segment profit, while the Formulation segment continued to post a loss of ₹72.93 lakhs. Operating cash flow was healthy at ₹997.62 lakhs, though the company invested ₹1,151.50 lakhs in property, plant and equipment, leading to a marginal dip in closing cash balance to ₹43.57 lakhs. The statutory auditor (Gokhale and Sathe) issued an unmodified opinion on the standalone results.
Results are mixed: profits are positive and the company is generating solid operating cash, but heavy capex is eating into cash reserves and the formulation business remains a drag. The recommended dividend signals confidence in earnings, while diversified related-party dealings with promoter family entities are worth monitoring for governance.